Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Overweight peptide evidence brief
A cited Overweight peptide evidence brief across 65 exact-label ClinicalTrials.gov records, 11 connected profiles, and 6 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
65 selected records.
11 profiles.
2015–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Overweight?
PeptideScanner’s selected collection contains 65 retained ClinicalTrials.gov records carrying the exact condition label “Overweight,” connected to 11 peptide profiles across 6 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Overweight, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 243 selected PubMed records and 9 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Overweight unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Overweight.
Eloralintide · source record 2026-08-15
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
PubMed lists PMID 41559929 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase I, Multicenter Study, with publication-date metadata of 2026-01-20 (day precision). PeptideScanner associated the retained record with the identity slug eloralintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Orforglipron · source record 2026-11-09
Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-11-12
Semaglutide and alcohol use disorder: An evidence gap India must fill.
PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Maridebart cafraglutide · source record 2026-08-13
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-11-15
Tirzepatide in Adolescents With Obesity: Research Summary.
PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Retatrutide · source record 2026-11-03
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00392925
PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- April 14, 2015
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00673387
PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- April 15, 2015
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00710814
PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- November 16, 2015
- Evidence lane
- Clinical trials
Exact-record source chronology
Overweight registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
58 recordsCagrilintide · 2026-11-16
ClinicalTrials.gov record NCT07220759
Active, not recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-11-12
ClinicalTrials.gov record NCT05556512
Active, not recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-11-10
ClinicalTrials.gov record NCT07232719
Active, not recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-11-10
ClinicalTrials.gov record NCT07400107
Active, not recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-11-09
ClinicalTrials.gov record NCT07871409
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-11-06
ClinicalTrials.gov record NCT07921316
Not yet recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-11-05
ClinicalTrials.gov record NCT07794579
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-11-04
ClinicalTrials.gov record NCT06672549
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-11-04
ClinicalTrials.gov record NCT06672939
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-04
ClinicalTrials.gov record NCT07282600
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-04
ClinicalTrials.gov record NCT07369011
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-04
ClinicalTrials.gov record NCT07392190
Recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-11-04
ClinicalTrials.gov record NCT07881458
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-11-03
ClinicalTrials.gov record NCT07900633
Not yet recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-11-02
ClinicalTrials.gov record NCT07908316
Recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-10-19
ClinicalTrials.gov record NCT07881770
Not yet recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-10-16
ClinicalTrials.gov record NCT07855133
Recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-10-16
ClinicalTrials.gov record NCT07868354
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-10-13
ClinicalTrials.gov record NCT07310563
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-10-13
ClinicalTrials.gov record NCT07790861
Not yet recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-10-09
ClinicalTrials.gov record NCT07215559
Active, not recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-10-08
ClinicalTrials.gov record NCT07589608
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-10-08
ClinicalTrials.gov record NCT07808060
Recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-09-30
ClinicalTrials.gov record NCT07850765
Completed at the retained observation.
Open cited registry record →Tirzepatide · 2026-09-29
ClinicalTrials.gov record NCT06603571
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-09-29
ClinicalTrials.gov record NCT07845578
Not yet recruiting at the retained observation.
Open cited registry record →Amycretin · 2026-09-28
ClinicalTrials.gov record NCT07720271
Recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-09-25
ClinicalTrials.gov record NCT07035093
Active, not recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-09-23
ClinicalTrials.gov record NCT07803744
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-09-22
ClinicalTrials.gov record NCT07321886
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-09-22
ClinicalTrials.gov record NCT07832799
Not yet recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-09-11
ClinicalTrials.gov record NCT05536804
Completed at the retained observation.
Open cited registry record →Petrelintide · 2026-09-09
ClinicalTrials.gov record NCT06926842
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-09-09
ClinicalTrials.gov record NCT07770841
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-09-04
ClinicalTrials.gov record NCT05872620
Completed at the retained observation.
Open cited registry record →Mazdutide · 2026-09-04
ClinicalTrials.gov record NCT07803705
Not yet recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-09-03
ClinicalTrials.gov record NCT07684144
Recruiting at the retained observation.
Open cited registry record →Amycretin · 2026-08-24
ClinicalTrials.gov record NCT07668401
Not yet recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-08-21
ClinicalTrials.gov record NCT05929066
Completed at the retained observation.
Open cited registry record →Eloralintide · 2026-08-20
ClinicalTrials.gov record NCT07738614
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-08-14
ClinicalTrials.gov record NCT05869903
Active, not recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-08-14
ClinicalTrials.gov record NCT07765511
Not yet recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-08-11
ClinicalTrials.gov record NCT06965413
Active, not recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-08-04
ClinicalTrials.gov record NCT07684235
Recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-08-04
ClinicalTrials.gov record NCT07745504
Not yet recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-07-31
ClinicalTrials.gov record NCT06993792
Active, not recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-07-30
ClinicalTrials.gov record NCT05929079
Completed at the retained observation.
Open cited registry record →Orforglipron · 2026-07-29
ClinicalTrials.gov record NCT06972459
Active, not recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-07-28
ClinicalTrials.gov record NCT07732426
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-07-24
ClinicalTrials.gov record NCT07037433
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-07-17
ClinicalTrials.gov record NCT06440980
Completed at the retained observation.
Open cited registry record →Eloralintide · 2026-07-16
ClinicalTrials.gov record NCT07665879
Recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-06-25
ClinicalTrials.gov record NCT07607587
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-06-24
ClinicalTrials.gov record NCT06230523
Completed at the retained observation.
Open cited registry record →Mazdutide · 2026-05-27
ClinicalTrials.gov record NCT07469800
Recruiting at the retained observation.
Open cited registry record →Orforglipron · 2026-05-22
ClinicalTrials.gov record NCT06186622
Completed at the retained observation.
Open cited registry record →Cagrilintide · 2026-04-13
ClinicalTrials.gov record NCT07411560
Recruiting at the retained observation.
Open cited registry record →Eloralintide · 2026-01-30
ClinicalTrials.gov record NCT06916065
Completed at the retained observation.
Open cited registry record →2025
1 recordEloralintide · 2025-11-19
ClinicalTrials.gov record NCT06916091
Completed at the retained observation.
Open cited registry record →2024
1 recordSemaglutide · 2024-08-30
ClinicalTrials.gov record NCT03574597
Completed at the retained observation.
Open cited registry record →2021
1 recordSemaglutide · 2021-11-11
ClinicalTrials.gov record NCT03611582
Completed at the retained observation.
Open cited registry record →2020
1 recordSemaglutide · 2020-12-24
ClinicalTrials.gov record NCT03842202
Completed at the retained observation.
Open cited registry record →2015
3 recordsMetreleptin · 2015-11-16
ClinicalTrials.gov record NCT00710814
Completed at the retained observation.
Open cited registry record →Metreleptin · 2015-04-15
ClinicalTrials.gov record NCT00673387
Completed at the retained observation.
Open cited registry record →Metreleptin · 2015-04-14
ClinicalTrials.gov record NCT00392925
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.